Ginsenoside Rh2
CAS No. 78214-33-2
Ginsenoside Rh2( Ginsenoside Rh2 | HY-N0605 | HY N0605 )
Catalog No. M19102 CAS No. 78214-33-2
Ginsenoside Rh2, an extract of red Panax ginseng, is a potent anti-inflammatory and anticancer drug.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 57 | In Stock |
|
| 5MG | 30 | In Stock |
|
| 10MG | 41 | In Stock |
|
| 25MG | 65 | In Stock |
|
| 50MG | 100 | In Stock |
|
| 100MG | 158 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGinsenoside Rh2
-
NoteResearch use only, not for human use.
-
Brief DescriptionGinsenoside Rh2, an extract of red Panax ginseng, is a potent anti-inflammatory and anticancer drug.
-
DescriptionGinsenoside Rh2 is an aldose reductase inhibitor found in Panax. It also decreases ROS levels in keratinocytes, lowers levels of amyloid-β in Alzheimer's disease models, induces β-cell proliferation, inhibits osteoclastogenesis by suppressing RANKL-induced osteoclast differentiation.(In Vitro):Ginsenoside Rh2 induces the activation of two initiator caspases, caspase-8 and caspase-9 in human cancer cells. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner and is therefore a promising candidate for anti-tumor drug development. Ginsenoside Rh2 triggers p53-dependent Fas expression and consequent activation of caspase-8 and p53-independent caspase-9-mediated intrinsic pathway to cause cancer cell death.The cytotoxic activity of Ginsenoside Rh2 in the human tumor cell lines HeLa, SK-HEP-1, SW480, and PC-3 is assessed by MTT. The cell viability of HeLa cells is remarkably inhibited by Ginsenoside Rh2, with an IC50 value of 2.52 μg/mL, whereas SK-HEP-1 and SW480 cells are less sensitive to Ginsenoside Rh2, with IC50 values of 3.15 μg/mL and 4.06 μg/mL, respectively. PC-3 cells are the least vulnerable to Ginsenoside Rh2, with an IC50 value of 7.85 μg/mL, 3-fold higher than HeLa cells.(In Vivo):A total of 15 days following B16-F10 cell injection, tumor sizes from the 3 tumor bearing groups are measured. The tumor sizes in the G-L group and G-H group (G-L and G-H refer to a low or high dose of ginsenoside Rh2 injection) are reduced compared with the tumor group (P<0.05). The survival analysis reveals that the Ginsenoside Rh2 treated groups survive longer than the untreated tumor group and the effect is dose-dependent (P<0.05).
-
In Vitro——
-
In Vivo——
-
SynonymsGinsenoside Rh2 | HY-N0605 | HY N0605
-
PathwayOthers
-
TargetOther Targets
-
RecptorEGFR
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number78214-33-2
-
Formula Weight622.87
-
Molecular FormulaC36H62O8
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 300 mg/mL; 481.64 mM
-
SMILESO[C@H]1[C@@H](O[C@@H]([C@H]([C@@H]1O)O)CO)O[C@@H]1C([C@H]2[C@@]([C@@H]3[C@]([C@]4([C@H]([C@@H](C3)O)[C@@H]([C@@](O)(CCC=C(C)C)C)CC4)C)(CC2)C)(CC1)C)(C)C
-
Chemical Name(2R,3R,4S,5S,6R)-2-(((3R,8R,9R,10R,12S,13R,14R,17S)-12-hydroxy-17-((S)-2-hydroxy-6-methylhept-5-en-2-yl)-4,4,8,10,14-pentamethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Confusarin
Confusarin (compound 12) is a phenanthrene compound that was isolated from F. fimbriata for the first time.
-
Melamine
Melamine is a widely-used intermediate mainly employed as a raw material for producing melamine resin. It is also a metabolite of cyromazine formed in the body of mammals who have ingested cyromazine.
-
Histrelin acetate
Histrelin acetate is a nonapeptide analog of gonadotropin-releasing hormone (GnRH) with added potency. It acts on particular cells of the pituitary gland called gonadotropes when present in the bloodstream. Histrelin stimulates these cells to release luteinizing hormone and follicle-stimulating hormone. Thus it is considered a gonadotropin-releasing hormone agonist or GnRH agonist.
Cart
sales@molnova.com